Stroke Treatment With Acute Reperfusion and Simvastatin

Summary

The purpose of this study is to determine whether simvastatin treatment started within the first 12 hours from stroke onset improves neurological and functional outcomes, evaluated at seventh day/discharge or at the third month.

Also, to demonstrate that simvastatin is safe and not associated with higher rates of hemorrhagic transformation in patients who receive thrombolysis.

Conditions

• Stroke, Acute

Interventions

DRUG

Simvastatin

Simvastatin 40 mgrs daily for three months.

Sponsors & Collaborators

• Hospital Universitari Vall d'Hebron Research Institute

  lead OTHER

Principal Investigators

• Joan Montaner, MD, PhD · Hospital Vall Hebron Research Institute

• Marc Ribó, MD, PhD · Hospital Vall Hebron. Stroke Unit

• Carmen Jimenez, MD · Hospital Son Dureta. Stroke Unit.

• Francesc Muñoz, MD · Hospital de Mollet

• David Canovas, MD · Consorci Sanitari Parc Taulí Sabadell.

• Jurek Krupinski, MD · Hospital Mutua de Terrassa. Neurology Department

• Maite Martinez-Zabaleta, MD · Hospital de Donostia. Neurology Department

• Francisco Javier De la Torre Laviana, MD · Hospital Virgen del Rocio. Stroke Unit.

• Marimar Freijo, MD · Hospital de Basurto

• Tomás Segura, MD · Hospital Universitario de Albacete

• Juan Arenillas, MD, PhD · Hospital Universitario de Valladolid

• Jose Manuel Flores, MD · Hospital de Ciudad Real

• Francisco Alonso, MD, PhD · Hospital General de Vic

• Jaime Masjuán Vallejo, MD · Hospital Universitario Ramón y Cajal. Stroke unit.

• Francisco Rubio Borrego, MD, PhD · Hospital Universitario de Bellvitge. Stroke Unit.

• Javier Tejada García, MD · Hospital de Leon

• Aida Lago Martín, MD, PhD · Hospital Universitario la Fe. Stroke Unit.

• Yolanda Bravo Anguiano, MD · Hospital General Yagüe

• Xavier Ustrell Roig, MD, PhD · Hospital Universitario Joan XXIII

• Francisco Purroy García, MD, PhD · Hospital Universitario Arnau de Vilanova de Lleida

• Raquel Delgado Mederos, MD, PhD · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2009-04-30

Primary Completion

2014-06-30

Completion

2014-06-30

Countries

• Spain

Study Locations